NEKTAR THERAPEUTICS WKN: 165417 ISIN: US6402681083 Kürzel: NKTR Forum: Aktien Thema: Hauptdiskussion

https://whtc.com/2022/04/14/nektar-bristol-myers-end-clinical-trial-program-for-cancer-drug-combo/ Nektar, Bristol Myers end clinical trial program for cancer drug combo

Sieht so aus

Dann war das wohl eine fehlivest 🤦🏻‍♂️

Bristol Myers Squibb and Nektar Announce Update on Phase 3 PIVOT IO-001 Trial Evaluating Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab) in Previously Untreated Unresectable or Metastatic Melanoma https://www.businesswire.com/news/home/20220313005021/en/Bristol-Myers-Squibb-and-Nektar-Announce-Update-on-Phase-3-PIVOT-IO-001-Trial-Evaluating-Bempegaldesleukin-BEMPEG-in-Combination-with-Opdivo-nivolumab-in-Previously-Untreated-Unresectable-or-Metastatic-Melanoma

Nektar tumbles after melanoma combo therapy trial fails https://www.reuters.com/business/healthcare-pharmaceuticals/bristol-myers-nektar-melanoma-combo-therapy-trial-fails-meet-main-goals-2022-03-14/

Nektar Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results https://www.prnewswire.com/news-releases/nektar-therapeutics-reports-fourth-quarter-and-year-end-2021-financial-results-301491992.html

https://www.prnewswire.com/news-releases/nektar-therapeutics-announces-phase-1b-data-for-novel-t-regulatory-cell-stimulator-nktr-358-ly3471851-in-patients-with-atopic-dermatitis-301445396.html Nektar Therapeutics Announces Phase 1b Data for Novel T Regulatory Cell Stimulator NKTR-358 (LY3471851) in Patients with Atopic Dermatitis

Nektar Therapeutics Reports Third Quarter 2021 Financial Results https://www.prnewswire.com/news-releases/nektar-therapeutics-reports-third-quarter-2021-financial-results-301417106.html

Gibt es News oder was ist hier los 😍

https://www.prnewswire.com/news-releases/nektar-announces-new-clinical-collaboration-with-merck-kgaa-darmstadt-germany-and-pfizer-inc-to-combine-nktr-255-a-novel-interleukin-15-agonist-with-avelumab-in-the-javelin-bladder-medley-study-301380966.html Nektar Therapeutics announced it has entered into a new oncology clinical collaboration with Merck KGaA, Darmstadt, Germany and Pfizer Inc. to evaluate the maintenance regimen of NKTR-255, Nektar's interleukin-15 (IL-15) receptor agonist, in combination with avelumab, a PD-L1 inhibitor, in patients with locally advanced or metastatic urothelial carcinoma (UC) in the Phase II JAVELIN Bladder Medley study. ...

Nektar Therapeutics Reports Second Quarter 2021 Financial Results https://www.prnewswire.com/news-releases/nektar-therapeutics-reports-second-quarter-2021-financial-results-301349775.html

A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and Nivolumab https://clinicaltrials.gov/ct2/show/NCT04955262 Recruitment Status  : Withdrawn (Did not initiate due to business reasons. IND is inactive.)

Gibt es News? Oder warum 5% hoch

Nektar Therapeutics Announces its First Publication of Preclinical Data Highlighting Anti-Tumor Properties of IL-15 Agonist, NKTR-255, in the Journal for ImmunoTherapy of Cancer (JITC) https://www.prnewswire.com/news-releases/nektar-therapeutics-announces-its-first-publication-of-preclinical-data-highlighting-anti-tumor-properties-of-il-15-agonist-nktr-255-in-the-journal-for-immunotherapy-of-cancer-jitc-301293169.html -- Results demonstrate NKTR-255's differentiated pharmacologic profile versus precomplexed IL-15 agonists, supporting its potential as a potent immunotherapy agent --

Nektar Therapeutics mit Zahlen zum abgelaufenen Quartal https://www.finanzen.at/nachrichten/aktien/nektar-therapeutics-mit-zahlen-zum-abgelaufenen-quartal-1030127215 Nektar Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results https://www.prnewswire.com/news-releases/nektar-therapeutics-reports-fourth-quarter-and-year-end-2020-financial-results-301236046.html

Nektar Therapeutics Breaks Out On Combo Study With Merck's Keytruda https://www.investors.com/news/technology/nktr-stock-breaks-out-plans-combo-study-merck-keytruda/?src=A00220